Biocryst Pharmaceuticals earnings were -$384.7M for the trailing 12 months ending Jun 30, 2026, with N/A growth year over year. The latest BCRX earnings report on Jun 30, 2026 announced Q2 2026 earnings of $78.4M, down 110.9% from last quarter. For the last reported fiscal year 2025 ending Dec 31, 2025, BCRX reported annual earnings of $263.9M, with -396.9% growth.
Biocryst Pharmaceuticals Earnings Reports & History FAQ
What were Biocryst Pharmaceuticals's earnings last quarter?
On BCRX's earnings call on Aug 5, 2026, Biocryst Pharmaceuticals (NASDAQ: BCRX) reported Q2 2026 earnings per share (EPS) of $0.31, up 1,450% year over year. Total BCRX earnings for the quarter were $78.40 million. In the same quarter last year, Biocryst Pharmaceuticals's earnings per share (EPS) was $0.02.
Is Biocryst Pharmaceuticals profitable or losing money?
As of the last Biocryst Pharmaceuticals earnings report, Biocryst Pharmaceuticals is currently losing money. Biocryst Pharmaceuticals's net profit (also called net income) for the twelve months ending Jun 30, 2026 was -$384.67 million, a 977.18% increase year over year.
What was BCRX's earnings growth in the past year?
As of Biocryst Pharmaceuticals's earnings date in Aug 5, 2026, Biocryst Pharmaceuticals's earnings has grown year over year. BCRX earnings in the past year totalled -$384.67 million.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.